Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Black Diamond Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BDTX
Nasdaq
8731
https://www.blackdiamondtherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Black Diamond Therapeutics Inc
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
- Apr 15th, 2024 4:00 pm
Black Diamond Therapeutics Announces Changes to Board of Directors
- Apr 11th, 2024 12:00 pm
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
- Apr 8th, 2024 1:55 pm
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
- Apr 7th, 2024 10:00 pm
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
- Apr 3rd, 2024 12:00 pm
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
- Mar 22nd, 2024 1:55 pm
Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...
- Mar 14th, 2024 9:31 am
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 12th, 2024 12:00 pm
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
- Mar 5th, 2024 9:30 pm
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 1:00 pm
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
- Jan 15th, 2024 10:49 am
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
- Jan 4th, 2024 1:00 pm
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
- Dec 13th, 2023 12:00 pm
With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backing
- Dec 5th, 2023 11:58 am
Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update
- Nov 6th, 2023 1:07 pm
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 6th, 2023 12:45 pm
Black Diamond Therapeutics Insider Ups Holding By 82% During Year
- Oct 25th, 2023 3:13 pm
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
- Oct 14th, 2023 4:30 pm
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 4th, 2023 4:14 pm
Black Diamond Therapeutics Announces CEO Transition
- Sep 18th, 2023 11:00 am
Scroll